ଇନସୁଲିନ ଡିଟେମିର

ଇନସୁଲିନ ଡିଟେମିର
Clinical data
Trade names	Levemir
AHFS/Drugs.com	monograph
MedlinePlus	a606012
data	EU EMA: yes; US DailyMed: Insulin_detemir;
Pregnancy; category	AU: B3 ; US: B (No risk in non-human studies) ; ;
Routes of; administration	Subcutaneous
Legal status
Legal status	UK: POM (Prescription only) ; US: ℞-only ; ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	60% (when administered s.c.)
Elimination half-life	5–7 hours
Duration of action	Up to 24 hours
Chemical and physical data
Formula	C267H402N64O76S6
Molar mass	୫,୯୧୬.୮୯ g·mol−1
(verify)

ଇନସୁଲିନ ଡିଟେମିର, ବ୍ୟବସାୟୀକ ନାମ ଲେଭେମିର, ଦୀର୍ଘକାଳୀନ କାର୍ଯ୍ୟକ୍ଷମ ଇନସୁଲିନ ଯାହା ଉଭୟ ଟାଇପ୍ 1 ଏବଂ ଟାଇପ୍ 2 ଡାଇବେଟିସ୍ ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ^[୬] ଏହା ଇଞ୍ଜେକସନ ଆକାରରେ ଚର୍ମ ତଳେ ଦିଆଯାଏ । ^[୫] ଏହା ୨୪ ଘଣ୍ଟା ପର୍ଯ୍ୟନ୍ତ ପ୍ରଭାବଶାଳୀ ରହେ ।^[୫]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କମ୍ ରକ୍ତ ଶର୍କରା, ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା, ଇଞ୍ଜେକ୍ସନ ସ୍ଥାନରେ ଯନ୍ତ୍ରଣା ଏବଂ ଓଜନ ବୃଦ୍ଧି ହୋଇପାରେ ।^[୬] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର ଏବଂ ସ୍ତନ୍ୟପାନ ନିରାପଦ ଦେଖାଯାଏ | ^[୭] ତନ୍ତୁ ଗ୍ରହଣ କରୁଥିବା ଗ୍ଲୁକୋଜର ପରିମାଣକୁ ବୃଦ୍ଧି କରି ଓ ଯକୃତଦ୍ୱାରା ପ୍ରସ୍ତୁତ ଗ୍ଲୁକୋଜର ପରିମାଣକୁ ହ୍ରାସ କରି ଏହା କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[୫]

ୟୁରୋପୀୟ ୟୁନିଅନରେ ୨୦୦୪ରେ ଏବଂ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୦୫ ମସିହାରେ ମେଡିକାଲ୍ ବ୍ୟବହାର ପାଇଁ ଇନସୁଲିନ ଡିଟେମିର ଅନୁମୋଦିତ ହୋଇଥିଲା । ^[୮] ^[୯] ^[୬] । ଯୁକ୍ତରାଜ୍ୟରେ ଏହାର ମୂଲ୍ୟ ୨୦୧୯ ମସିହାରେ ୧୦୦ ୟୁନିଟ ନିମନ୍ତେ ୨.୮୦ ପାଉଣ୍ଡ ଥିଲା । ^[୧୦] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ହୋଲସେଲ ମୂଲ୍ୟ ପ୍ରାୟ ୨୯.୫୦ ଡଲାର ଅଟେ ।^[୧୧] 2017 ରେ, ଏହା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୧୧୪ତମ ସାଧାରଣ ପ୍ରେସକ୍ରିପସନ୍ ଔଷଧ ଥିଲା, ଯେଉଁଥିରେ ଛଅ ଲକ୍ଷରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ୍ ରହିଥିଲା ।^[୧୨] ^[୧୩]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Insulin detemir (Levemir) Use During Pregnancy". Drugs.com. 12 June 2019. Archived from the original on 13 June 2019. Retrieved 14 April 2020.
↑ "Levemir FlexPen 100 units/ml solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Archived from the original on 7 January 2021. Retrieved 14 April 2020.
↑ "Levemir InnoLet 100 units/ml solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Archived from the original on 8 January 2021. Retrieved 14 April 2020.
↑ "Levemir Penfill 100 units/ml solution for injection in cartridge - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Archived from the original on 7 January 2021. Retrieved 14 April 2020.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ "Insulin Detemir Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 19 March 2016. Retrieved 3 March 2019.
↑ ^୬.୦ ^୬.୧ ^୬.୨ "Insulin Detemir Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 19 March 2016. Retrieved 3 March 2019.
↑ "Insulin detemir (Levemir) Use During Pregnancy". Drugs.com. 12 June 2019. Archived from the original on 13 June 2019. Retrieved 14 April 2020.
↑ "Drug Approval Package: Levemir Insulin Detemir[rDNA origin] Injection; NDA #021536". U.S. Food and Drug Administration (FDA). 26 July 2005. Archived from the original on 6 May 2015. Retrieved 14 April 2020.
↑ "Levemir EPAR". European Medicines Agency (EMA). Archived from the original on 5 July 2019. Retrieved 14 April 2020.
↑ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 701. ISBN 9780857113382.
↑ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
↑ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
↑ "Insulin Detemir - Drug Usage Statistics". ClinCalc. Archived from the original on 12 April 2020. Retrieved 11 April 2020.

[autogen1-1] ୧.୦ ^୧.୧ "Insulin detemir (Levemir) Use During Pregnancy". Drugs.com. 12 June 2019. Archived from the original on 13 June 2019. Retrieved 14 April 2020.

[2] "Levemir FlexPen 100 units/ml solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Archived from the original on 7 January 2021. Retrieved 14 April 2020.

[3] "Levemir InnoLet 100 units/ml solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Archived from the original on 8 January 2021. Retrieved 14 April 2020.

[4] "Levemir Penfill 100 units/ml solution for injection in cartridge - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Archived from the original on 7 January 2021. Retrieved 14 April 2020.

[autogen2-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ "Insulin Detemir Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 19 March 2016. Retrieved 3 March 2019.

[AHFS2019-6] ୬.୦ ^୬.୧ ^୬.୨ "Insulin Detemir Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 19 March 2016. Retrieved 3 March 2019.

[Preg2019-7] "Insulin detemir (Levemir) Use During Pregnancy". Drugs.com. 12 June 2019. Archived from the original on 13 June 2019. Retrieved 14 April 2020.

[8] "Drug Approval Package: Levemir Insulin Detemir[rDNA origin] Injection; NDA #021536". U.S. Food and Drug Administration (FDA). 26 July 2005. Archived from the original on 6 May 2015. Retrieved 14 April 2020.

[Levemir_EPAR-9] "Levemir EPAR". European Medicines Agency (EMA). Archived from the original on 5 July 2019. Retrieved 14 April 2020.

[BNF76-10] British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 701. ISBN 9780857113382.

[NADAC2019-11] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[ref-12] "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.

[ref1-13] "Insulin Detemir - Drug Usage Statistics". ClinCalc. Archived from the original on 12 April 2020. Retrieved 11 April 2020.

[୬]

[୫]

[୧]

[୨]

[୩]

[୪]

[୭]

[୮]

[୯]

[୧୦]

[୧୧]

[୧୨]

[୧୩]